Sepsis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sepsis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Sepsis - Pipeline Review, H1 2015’, provides an overview of the Sepsis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Sepsis Overview 9
Therapeutics Development 10
Pipeline Products for Sepsis - Overview 10
Pipeline Products for Sepsis - Comparative Analysis 11
Sepsis - Therapeutics under Development by Companies 12
Sepsis - Therapeutics under Investigation by Universities/Institutes 16
Sepsis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Sepsis - Products under Development by Companies 21
Sepsis - Products under Investigation by Universities/Institutes 26
Sepsis - Companies Involved in Therapeutics Development 27
Adrenomed AG 27
Altor BioScience Corporation 28
Am-Pharma B.V. 29
Arch Biopartners, Inc. 30
Asahi Kasei Pharma Corp. 31
Baxter International Inc. 32
Biomedica Management Corporation 33
Chiesi Farmaceutici SpA 34
Chiome Bioscience, Inc. 35
Cilian AG 36
Cognosci, Inc. 37
Diomune S.L 38
Endacea, Inc. 39
Evec, Inc. 40
Huons Co., Ltd. 41
Immune Response BioPharma, Inc. 42
ImmunNovative Developments SL 43
InflaRx GmbH 44
Integrated BioTherapeutics, Inc. 45
ISU ABXIS Co.,Ltd. 46
Lead Discovery Center GmbH 47
MSM Protein Technologies, Inc. 48
Navigen Pharmaceuticals, Inc. 49
Novadiscovery SAS 50
Noxxon Pharma AG 51
Ocata Therapeutics, Inc. 52
OncoImmune, Inc. 53
Opsona Therapeutics Ltd. 54
ProThera Biologics, LLC. 55
Silence Therapeutics plc 56
Stemedica Cell Technologies, Inc. 57
Syntiron LLC 58
Takeda Pharmaceutical Company Limited 59
TiGenix NV 60
XImmune AB 61
Sepsis - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Target 63
Assessment by Mechanism of Action 65
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
3K3A-APC - Drug Profile 71
AB-022 - Drug Profile 73
AcPepA - Drug Profile 74
adrecizumab - Drug Profile 75
Alpha B Crystalline - Drug Profile 76
ALT-836 - Drug Profile 77
AM/AMBP-1 - Drug Profile 79
Anti-Semaphorin 3A Antibodies - Drug Profile 81
Aspidasept - Drug Profile 82
Atu-111 - Drug Profile 83
BaxB-01 - Drug Profile 84
BaxG-03 - Drug Profile 85
BaxM-159 - Drug Profile 86
BRL-44408 - Drug Profile 87
BTZO-2 - Drug Profile 88
CN-16 - Drug Profile 89
COG-133 - Drug Profile 90
Combpath-5.0 - Drug Profile 92
Combpath-6.0 - Drug Profile 93
Cx-611 - Drug Profile 94
Drug for Sepsis - Drug Profile 96
Drugs for Sepsis - Drug Profile 97
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 98
Drugs to Inhibit Sialidase for Sepsis - Drug Profile 99
Escherichia coli vaccine - Drug Profile 100
EV-007156 - Drug Profile 101
Glyco-23 - Drug Profile 102
HBN-1 - Drug Profile 103
HBN-3 - Drug Profile 104
HBN-4 - Drug Profile 105
HU-003 - Drug Profile 106
IFX-1 - Drug Profile 107
ImmStem - Drug Profile 108
ImmuneSafe - Drug Profile 109
IND-005 - Drug Profile 110
IND-006 - Drug Profile 111
IR-999 - Drug Profile 112
ISU-201 - Drug Profile 113
Klebsiella pneumoniae vaccine - Drug Profile 114
L-97-1 - Drug Profile 115
LB-1148 - Drug Profile 117
LR-17 - Drug Profile 118
M-33 - Drug Profile 119
meropenem - Drug Profile 120
Mesenchymal Stem Cells - Drug Profile 121
Metablok - Drug Profile 123
Micselon - Drug Profile 124
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 125
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 126
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 127
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 128
MSM-236 - Drug Profile 130
Nanotherapeutics - Drug Profile 131
NAV-838 - Drug Profile 132
NOXD-19 - Drug Profile 134
OPN-305 - Drug Profile 135
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 137
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 138
Recombinant Enzyme for Sepsis - Drug Profile 139
Recombinant Human Alkaline Phosphatase - Drug Profile 140
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 142
Recombinant Protein for Sepsis - Drug Profile 143
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile 144
Slit2N - Drug Profile 145
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 147
Small Molecule for Sepsis - Drug Profile 148
Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile 149
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 150
Small Molecules to Inhibit LPS for Bacterial Sepsis - Drug Profile 151
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 152
staphylococcus aureus (bivalent) vaccine - Drug Profile 153
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 154
Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile 155
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 156
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 157
Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile 158
Synthetic Peptides to Inhibit HSP90 for Oncology, Septic Shock, Inflammatory and Infectious Diseases - Drug Profile 159
Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile 160
thrombomodulin alfa - Drug Profile 161
TRX-306 - Drug Profile 163
vancomycin - Drug Profile 164
Yersinia pestis vaccine - Drug Profile 165
Sepsis - Recent Pipeline Updates 166
Sepsis - Dormant Projects 176
Sepsis - Discontinued Products 180
Sepsis - Product Development Milestones 182
Featured News & Press Releases 182
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables

Number of Products under Development for Sepsis, H1 2015 16
Number of Products under Development for Sepsis - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Comparative Analysis by Unknown Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Sepsis - Pipeline by Adrenomed AG, H1 2015 33
Sepsis - Pipeline by Altor BioScience Corporation, H1 2015 34
Sepsis - Pipeline by Am-Pharma B.V., H1 2015 35
Sepsis - Pipeline by Arch Biopartners, Inc., H1 2015 36
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H1 2015 37
Sepsis - Pipeline by Baxter International Inc., H1 2015 38
Sepsis - Pipeline by Biomedica Management Corporation, H1 2015 39
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H1 2015 40
Sepsis - Pipeline by Chiome Bioscience, Inc., H1 2015 41
Sepsis - Pipeline by Cilian AG, H1 2015 42
Sepsis - Pipeline by Cognosci, Inc., H1 2015 43
Sepsis - Pipeline by Diomune S.L, H1 2015 44
Sepsis - Pipeline by Endacea, Inc., H1 2015 45
Sepsis - Pipeline by Evec, Inc., H1 2015 46
Sepsis - Pipeline by Huons Co., Ltd., H1 2015 47
Sepsis - Pipeline by Immune Response BioPharma, Inc., H1 2015 48
Sepsis - Pipeline by ImmunNovative Developments SL, H1 2015 49
Sepsis - Pipeline by InflaRx GmbH, H1 2015 50
Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H1 2015 51
Sepsis - Pipeline by ISU ABXIS Co.,Ltd., H1 2015 52
Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2015 53
Sepsis - Pipeline by MSM Protein Technologies, Inc., H1 2015 54
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 55
Sepsis - Pipeline by Novadiscovery SAS, H1 2015 56
Sepsis - Pipeline by Noxxon Pharma AG, H1 2015 57
Sepsis - Pipeline by Ocata Therapeutics, Inc., H1 2015 58
Sepsis - Pipeline by OncoImmune, Inc., H1 2015 59
Sepsis - Pipeline by Opsona Therapeutics Ltd., H1 2015 60
Sepsis - Pipeline by ProThera Biologics, LLC., H1 2015 61
Sepsis - Pipeline by Silence Therapeutics plc, H1 2015 62
Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 63
Sepsis - Pipeline by Syntiron LLC, H1 2015 64
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 65
Sepsis - Pipeline by TiGenix NV, H1 2015 66
Sepsis - Pipeline by XImmune AB, H1 2015 67
Assessment by Monotherapy Products, H1 2015 68
Number of Products by Stage and Target, H1 2015 70
Number of Products by Stage and Mechanism of Action, H1 2015 72
Number of Products by Stage and Route of Administration, H1 2015 74
Number of Products by Stage and Molecule Type, H1 2015 76
Sepsis Therapeutics - Recent Pipeline Updates, H1 2015 172
Sepsis - Dormant Projects, H1 2015 182
Sepsis - Dormant Projects (Contd..1), H1 2015 183
Sepsis - Dormant Projects (Contd..2), H1 2015 184
Sepsis - Dormant Projects (Contd..3), H1 2015 185
Sepsis - Discontinued Products, H1 2015 186
Sepsis - Discontinued Products (Contd..1), H1 2015 187